DPYD*2A mutation: the most common mutation associated with DPD deficiency.
about
Systemic therapies for pancreatic cancer--the role of pharmacogeneticsAssociation of new deletion/duplication region at chromosome 1p21 with intellectual disability, severe speech deficit and autism spectrum disorder-like behavior: an all-in approach to solving the DPYD enigmaHigh-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity.Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.Can You Determine the Cause of This Patient's Skin Changes?Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer.Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.Screening of dihydropyrimidine dehydrogenase genetic variants by direct sequencing in different ethnic groups.Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications.Clinically relevant cancer biomarkers and pharmacogenetic assays.Pharmacogenetics in dermatology: a patient-centered update.Application of genotype-guided cancer therapy in solid tumors.Translational genomics and head and neck cancer: toward precision medicine.Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant.Acquired factor VII deficiency following FOLFOX in a patient with colorectal cancer who was also DPD deficient.Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients.PharmGKB summary: fluoropyrimidine pathwaysLethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation(13)C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients.Pharmacogenetic landscape of DPYD variants in south Asian populations by integration of genome-scale data.
P2860
Q27021716-E66D39F9-0890-437D-B955-4BE281F68D37Q28596636-81DECBCD-9734-4CE7-B961-5C5835ACE53FQ33405398-7D1766F4-3150-4DD3-A0CD-5EB095798F79Q33432892-DC7B225C-D59B-461E-B617-87419D4AFFA2Q33885684-3DD1A9BB-782D-453E-8529-A918659EEF94Q35048269-B4AAD02C-ADFF-4CD8-A258-506684C40EC0Q35584977-2E6DEACB-41FE-42FE-B3BC-C2C67A7DBF96Q36250758-E577AFC4-A03C-4810-8EA0-32701A99F467Q37098042-47EB286C-CC37-45B7-82C3-8DD2FF8C27D9Q37866805-F6BEB19A-777B-44F9-8F1E-5AECC03E9633Q38077041-8983AB9D-7455-482A-A105-56646E5261EFQ38115822-6D60DEF8-B3C0-4121-81B7-0E5E1D7FFB9EQ38170457-EE62CD36-335B-4C94-AC60-CA847BD62FE3Q38241804-F34BED98-341F-415B-9468-AD8915A3C745Q40127619-CEE5A548-6452-4FEC-9613-263B211A6310Q41320206-FE4F5F78-1A33-4DE6-909E-8635070C8DA9Q42018846-57B49DF9-247F-4C0C-ADEE-42F985111C97Q42178970-E45A58D3-09B1-44F8-BD27-31E1FAF734EAQ42673945-B9F18350-8AC6-4C47-9C78-8888FD6C33D2Q43817078-FE5D5948-C8D9-49E8-8A27-5125C5340375Q47312464-D32CE4BA-C895-4827-BE3A-33C886106EC8
P2860
DPYD*2A mutation: the most common mutation associated with DPD deficiency.
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
DPYD*2A mutation: the most common mutation associated with DPD deficiency.
@ast
DPYD*2A mutation: the most common mutation associated with DPD deficiency.
@en
type
label
DPYD*2A mutation: the most common mutation associated with DPD deficiency.
@ast
DPYD*2A mutation: the most common mutation associated with DPD deficiency.
@en
prefLabel
DPYD*2A mutation: the most common mutation associated with DPD deficiency.
@ast
DPYD*2A mutation: the most common mutation associated with DPD deficiency.
@en
P2093
P1476
DPYD*2A mutation: the most common mutation associated with DPD deficiency.
@en
P2093
Hany Ezzeldin
Katisha Vance
Robert B Diasio
Sandra Sellers
P2888
P304
P356
10.1007/S00280-006-0392-5
P577
2006-12-13T00:00:00Z
P5875
P6179
1015087525